Navigation Links
Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders

TUSTIN, Calif., Nov. 4, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced that all six proxy resolutions passed at a special meeting of shareholders today.

The Company's proxy statement was filed with the Securities and Exchange Commission on October 14, 2011 is available at and on the Company's web site: Radient Pharmaceuticals also announced that it has retained E & E Communications, Laguna Hills, California, and its principal, Paul Knopick, to assist with its public and investor relations program.

The following table is intended to provide the latest information on Radient's business metrics.Radient's Business MetricsCash on hand: $165,000*

*Approximate amount as of November 2, 2011Common Shares Outstanding:  647 million*

*Approximate number as of November 2, 2011.

  750 million shares authorized.Outstanding Warrants & Options:  110 million*

*Approximate number as of November 2, 2011About Radient Pharmaceuticals:Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit

Forward-Looking Statements:Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Paul Knopick
E & E Communications


SOURCE Radient Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient
2. Thermal Gradient Announces Breakthrough in Fast PCR Device Technology
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... They call it the ... network, a depiction of a system of linkages and connections so complex and ... professor of computer science at Worcester Polytechnic Institute (WPI) and director of the ...
(Date:10/12/2017)... JOHNSTON, Iowa (PRWEB) , ... October 12, 2017 ... ... company based in Vilnius, Lithuania, announced today that they have entered into a ... collaboration is to provide CRISPR researchers with additional tools for gene editing across ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Wound Market with the addition of its newest module, US Hemostats & Sealants. ... for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... launched Rosalindâ„¢, the first-ever genomics analysis platform specifically designed for life science ... in honor of pioneering researcher Rosalind Franklin, who made a major contribution ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):